DaVita Inc., formerly DaVita HealthCare Partners Inc., operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. Its DMG division is a patient- and physician-focused integrated healthcare delivery and management company that provides medical services to members through capitation contracts. Its segments include U.S. dialysis and related lab services, DMG, and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2016, it had operated or provided administrative services to 154 outpatient dialysis centers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Healthcare Facilities & Services - NEC
- Sub-Industry: Health Care Services
- Symbol: NYSE:DVA
- CUSIP: 23918K10
- Web: www.davita.com
Capitalization:- Market Cap: $10.75118 billion
- Outstanding Shares: 191,199,000
Average Prices:- 50 Day Moving Avg: $61.57
- 200 Day Moving Avg: $65.36
- 52 Week Range: $54.50 - $70.16
P/E:- Trailing P/E Ratio: 8.60
- Foreward P/E Ratio: 14.82
- P/E Growth: 1.35
Sales & Book Value:- Annual Revenue: $15.01 billion
- Price / Sales: 0.72
- Book Value: $26.59 per share
- Price / Book: 2.12
Profitability:- EBIDTA: $2.45 billion
- Net Margins: 8.68%
- Return on Equity: 14.02%
- Return on Assets: 3.78%
Debt:- Debt-to-Equity Ratio: 1.69%
- Current Ratio: 1.45%
- Quick Ratio: 1.38%
Misc:- Average Volume: 1.43 million shs.
- Beta: 0.89
- Short Ratio: 4.52
Frequently Asked Questions for DaVita HealthCare Partners (NYSE:DVA)
What is DaVita HealthCare Partners' stock symbol?
DaVita HealthCare Partners trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."
How were DaVita HealthCare Partners' earnings last quarter?
DaVita HealthCare Partners Inc. (NYSE:DVA) released its earnings results on Tuesday, August, 1st. The company reported $0.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.90 by $0.02. The business had revenue of $3.88 billion for the quarter, compared to analysts' expectations of $3.82 billion. DaVita HealthCare Partners had a net margin of 8.68% and a return on equity of 14.02%. The company's quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the company earned $1.01 earnings per share. View DaVita HealthCare Partners' Earnings History.
When will DaVita HealthCare Partners make its next earnings announcement?
Where is DaVita HealthCare Partners' stock going? Where will DaVita HealthCare Partners' stock price be in 2017?
9 brokers have issued 12 month target prices for DaVita HealthCare Partners' stock. Their forecasts range from $62.00 to $75.00. On average, they expect DaVita HealthCare Partners' share price to reach $67.88 in the next year. View Analyst Ratings for DaVita HealthCare Partners.
Who are some of DaVita HealthCare Partners' key competitors?
Some companies that are related to DaVita HealthCare Partners include Laboratory Corporation of America Holdings (LH), Quest Diagnostics Incorporated (DGX), Universal Health Services (UHS), NMC Health PLC (NMC), HealthSouth Corporation (HLS), Acadia Healthcare Company (ACHC), Mednax (MD), Molina Healthcare (MOH), Chemed (CHE), LifePoint Health (LPNT), Select Medical Holdings Corporation (SEM), Udg Healthcare PLC (UDG), HMS Holdings Corp (HMSY), Tenet Healthcare Corporation (THC), China Cord Blood Corporation (CO), Community Health Systems (CYH), HealthStream (HSTM) and Kindred Healthcare (KND).
Who are DaVita HealthCare Partners' key executives?
DaVita HealthCare Partners' management team includes the folowing people:
- Kent J. Thiry, Chairman of the Board
- James K. Hilger, Interim Chief Financial Officer, Chief Accounting Officer
- Joel Ackerman, Chief Financial Officer
- Robert Lang, President, International Business
- Javier J. Rodriguez, Chief Executive Officer - Kidney Care
- Jeanine M. Jiganti, Chief Compliance Officer
- LeAnne M. Zumwalt, Group Vice President - purchasing and government affairs
- Michael D. Staffieri, Chief Operating Officer- Kidney Care
- Kathleen Alyce Waters, Chief Legal Officer
- Peter T. Grauer, Lead Director, Independent Director
Who owns DaVita HealthCare Partners stock?
DaVita HealthCare Partners' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Berkshire Hathaway Inc. (20.17%), California Public Employees Retirement System (0.25%), PGGM Investments (0.23%), Canada Pension Plan Investment Board (0.20%), Rhumbline Advisers (0.16%) and Hikari Power Ltd (0.15%). Company insiders that own DaVita HealthCare Partners stock include Charles Berg, Dennis Kogod, James K Hilger, Javier Rodriguez, Jeanine Marie Jiganti, John M Nehra, Kent J Thiry, Kim M Rivera, Laura Mildenberger, Leanne M Zumwalt, Michael David Staffieri, Pamela M Arway, Roger Valine and William L Roper. View Institutional Ownership Trends for DaVita HealthCare Partners.
Who sold DaVita HealthCare Partners stock? Who is selling DaVita HealthCare Partners stock?
DaVita HealthCare Partners' stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Russell Investments Group Ltd., Rhumbline Advisers, Investment House LLC, Aperio Group LLC, Exxonmobil Investment Management Inc. TX and Peloton Wealth Strategists. Company insiders that have sold DaVita HealthCare Partners stock in the last year include Charles Berg, Javier Rodriguez and William L Roper. View Insider Buying and Selling for DaVita HealthCare Partners.
Who bought DaVita HealthCare Partners stock? Who is buying DaVita HealthCare Partners stock?
DaVita HealthCare Partners' stock was purchased by a variety of institutional investors in the last quarter, including PGGM Investments, Canada Pension Plan Investment Board, Airain ltd, Oak Associates Ltd. OH, Mn Services Vermogensbeheer B.V., Deane Retirement Strategies Inc., Schroder Investment Management Group and Flinton Capital Management LLC. View Insider Buying and Selling for DaVita HealthCare Partners.
How do I buy DaVita HealthCare Partners stock?
Shares of DaVita HealthCare Partners can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DaVita HealthCare Partners' stock price today?
One share of DaVita HealthCare Partners stock can currently be purchased for approximately $56.47.
MarketBeat Community Rating for DaVita HealthCare Partners (NYSE DVA)MarketBeat's community ratings are surveys of what our community members think about DaVita HealthCare Partners and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for DaVita HealthCare Partners (NYSE:DVA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.11) |
| Consensus Price Target: | $67.88 (20.20% upside) |
Analysts' Ratings History for DaVita HealthCare Partners (NYSE:DVA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/3/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $70.00 | Medium |  |
| 5/25/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Sell | $62.00 | High | |
| 2/17/2017 | Royal Bank Of Canada | Reiterated Rating | Hold | $62.00 | N/A | |
| 12/13/2016 | Robert W. Baird | Downgrade | Outperform -> Neutral | $68.00 -> $69.00 | N/A | |
| 11/21/2016 | Bank of America Corporation | Reiterated Rating | Hold | $68.00 | N/A | |
| 11/1/2016 | Wells Fargo & Company | Reiterated Rating | Outperform | | N/A | |
| 10/13/2016 | SunTrust Banks, Inc. | Set Price Target | Hold | $66.00 | N/A | |
| 9/20/2016 | Raymond James Financial, Inc. | Upgrade | Market Perform -> Outperform | $75.00 | N/A | |
| 9/6/2016 | Citigroup Inc. | Initiated Coverage | Neutral | $71.00 | N/A | |
| 8/9/2016 | J P Morgan Chase & Co | Boost Price Target | Neutral | $74.00 -> $75.00 | N/A | |
| 4/6/2016 | Susquehanna Bancshares Inc | Boost Price Target | Neutral | $70.00 -> $78.00 | N/A | |
| 3/2/2016 | Sanford C. Bernstein | Lower Price Target | Market Perform | $74.50 -> $71.00 | N/A | |
| 2/12/2016 | William Blair | Reiterated Rating | Buy | | N/A | |
| 2/12/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $90.00 -> $85.00 | N/A | |
(Data available from 8/22/2015 forward)
Earnings History for DaVita HealthCare Partners (NYSE:DVA)Earnings History by Quarter for DaVita HealthCare Partners (NYSE DVA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | $0.94 | | | | | N/A | |
| 8/1/2017 | Q2 2017 | $0.90 | $0.92 | $3.82 billion | $3.88 billion | View | Listen | |
| 5/2/2017 | Q1 2017 | $0.82 | $0.79 | $3.69 billion | $3.70 billion | View | Listen | |
| 2/16/2017 | Q4 2016 | $0.91 | $0.98 | $3.74 billion | $3.72 billion | View | Listen | |
| 11/2/2016 | Q316 | $0.94 | $0.95 | $3.72 billion | $3.73 billion | View | Listen | |
| 8/8/2016 | Q216 | $0.98 | $1.01 | $3.67 billion | $3.72 billion | View | Listen | |
| 5/4/2016 | Q116 | $0.86 | $0.92 | $3.51 billion | $3.58 billion | View | Listen | |
| 2/11/2016 | Q415 | $0.97 | $1.01 | $3.50 billion | $3.53 billion | View | Listen | |
| 11/3/2015 | Q315 | $0.97 | $1.00 | $3.46 billion | $3.53 billion | View | Listen | |
| 8/4/2015 | Q215 | $0.95 | $0.95 | $3.37 billion | $3.43 billion | View | Listen | |
| 5/4/2015 | Q115 | $0.86 | $0.86 | $3.25 billion | $3.29 billion | View | Listen | |
| 2/12/2015 | Q414 | $0.89 | $0.96 | $3.26 billion | $3.33 billion | View | Listen | |
| 11/6/2014 | Q314 | $0.91 | $0.90 | $3.19 billion | $3.25 billion | View | Listen | |
| 7/31/2014 | Q214 | $0.88 | $0.95 | $3.10 billion | $3.17 billion | View | Listen | |
| 5/1/2014 | Q1 | $0.87 | $0.85 | $3.02 billion | $3.04 billion | View | Listen | |
| 2/11/2014 | Q413 | $1.91 | $0.99 | $2.92 billion | $3.06 billion | View | Listen | |
| 11/5/2013 | Q313 | $0.96 | $0.98 | $2.93 billion | $3.00 billion | View | Listen | |
| 8/6/2013 | Q2 2013 | $1.84 | $1.84 | $2.88 billion | $2.87 billion | View | Listen | |
| 5/7/2013 | Q1 2013 | $1.80 | $1.84 | $2.78 billion | $2.83 billion | View | Listen | |
| 2/14/2013 | Q4 2012 | $1.60 | $1.85 | $2.40 billion | $2.48 billion | View | Listen | |
| 10/30/2012 | | $1.55 | $1.56 | | | View | N/A | |
| 8/1/2012 | | $1.47 | $1.49 | | | View | N/A | |
| 2/16/2012 | | $1.49 | $1.58 | | | View | N/A | |
| 11/3/2011 | | $1.46 | $1.45 | | | View | N/A | |
| 8/3/2011 | | $1.14 | $1.17 | | | View | N/A | |
| 5/2/2011 | | $0.95 | $0.96 | | | View | N/A | |
| 2/10/2011 | | $1.12 | $0.70 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for DaVita HealthCare Partners (NYSE:DVA)2017 EPS Consensus Estimate: $3.55
2018 EPS Consensus Estimate: $3.82
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.77 | $0.84 | $0.81 |
| Q2 2017 | 3 | $0.90 | $0.92 | $0.91 |
| Q3 2017 | 3 | $0.90 | $0.95 | $0.93 |
| Q4 2017 | 3 | $0.90 | $0.91 | $0.91 |
| Q1 2018 | 2 | $0.85 | $0.85 | $0.85 |
| Q2 2018 | 2 | $0.97 | $0.99 | $0.98 |
| Q3 2018 | 2 | $0.99 | $1.03 | $1.01 |
| Q4 2018 | 2 | $0.97 | $0.99 | $0.98 |
(Data provided by Zacks Investment Research)
Dividend History for DaVita HealthCare Partners (NYSE:DVA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for DaVita HealthCare Partners (NYSE:DVA)Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 83.53%
Insider Trades by Quarter for DaVita HealthCare Partners (NYSE:DVA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/15/2017 | Javier Rodriguez | CEO | Sell | 1,294 | $66.21 | $85,675.74 | |
| 5/9/2017 | Charles Berg | Director | Sell | 8,414 | $65.80 | $553,641.20 | |
| 5/4/2017 | William L Roper | Director | Sell | 12,994 | $65.89 | $856,174.66 | |
| 8/9/2016 | Michael David Staffieri | COO | Sell | 20,262 | $73.09 | $1,480,949.58 | |
| 7/11/2016 | Jeanine Marie Jiganti | Insider | Sell | 1,291 | $78.51 | $101,356.41 | |
| 7/1/2016 | Jeanine Marie Jiganti | Insider | Sell | 4,620 | $77.45 | $357,819.00 | |
| 5/25/2016 | Pamela M Arway | Director | Sell | 10,824 | $77.16 | $835,179.84 | |
| 5/23/2016 | James K Hilger | CFO | Sell | 3,416 | $76.79 | $262,314.64 | |
| 5/20/2016 | Kent J Thiry | CEO | Sell | 32,880 | $76.99 | $2,531,431.20 | |
| 5/17/2016 | Dennis Kogod | CEO | Sell | 17,700 | $77.35 | $1,369,095.00 | |
| 5/17/2016 | Leanne M Zumwalt | VP | Sell | 538 | $77.08 | $41,469.04 | |
| 5/16/2016 | James K Hilger | CFO | Sell | 3,983 | $75.59 | $301,074.97 | |
| 5/16/2016 | Javier Rodriguez | CEO | Sell | 36,466 | $75.44 | $2,750,995.04 | |
| 5/16/2016 | Michael David Staffieri | COO | Sell | 4,934 | $75.69 | $373,454.46 | |
| 5/12/2016 | Roger Valine | Director | Sell | 8,220 | $76.34 | $627,514.80 | |
| 5/10/2016 | Dennis Kogod | CEO | Sell | 40,048 | $76.25 | $3,053,660.00 | |
| 5/6/2016 | John M Nehra | Director | Sell | 16,314 | $75.56 | $1,232,685.84 | |
| 4/11/2016 | Javier Rodriguez | CEO | Sell | 89,912 | $73.51 | $6,609,431.12 | |
| 3/21/2016 | Dennis Kogod | CEO | Sell | 13,455 | $72.12 | $970,374.60 | |
| 2/29/2016 | Pamela M Arway | Director | Sell | 9,026 | $66.00 | $595,716.00 | |
| 2/23/2016 | Leanne M. Zumwalt | VP | Sell | 14,587 | $64.25 | $937,214.75 | |
| 2/16/2016 | Dennis Kogod | CEO | Sell | 33,290 | $61.99 | $2,063,647.10 | |
| 12/17/2015 | Laura Mildenberger | insider | Sell | 1,440 | $68.14 | $98,121.60 | |
| 9/22/2015 | Kim M. Rivera | insider | Sell | 40,037 | $75.48 | $3,021,992.76 | |
| 8/17/2015 | Carol Anthony Davidson | Director | Sell | 4,038 | $79.93 | $322,757.34 | |
| 6/4/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $83.39 | $2,618,446.00 | |
| 5/28/2015 | Michael David Staffieri | COO | Sell | 9,050 | $84.07 | $760,833.50 | |
| 5/19/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $83.22 | $1,306,554.00 | |
| 5/18/2015 | James K Hilger | CFO | Sell | 3,983 | $82.10 | $327,004.30 | |
| 5/18/2015 | Michael David Staffieri | COO | Sell | 2,047 | $82.03 | $167,915.41 | |
| 5/18/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $82.24 | $1,291,168.00 | |
| 5/11/2015 | James K Hilger | CFO | Sell | 8,267 | $82.00 | $677,894.00 | |
| 5/11/2015 | Jeanine Marie Jiganti | Insider | Sell | 2,481 | $81.95 | $203,317.95 | |
| 5/11/2015 | John M Nehra | Director | Sell | 12,278 | $81.85 | $1,004,954.30 | |
| 4/21/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $82.40 | $2,587,360.00 | |
| 4/7/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $82.15 | $1,289,755.00 | |
| 4/6/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $81.49 | $1,279,393.00 | |
| 3/27/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $81.18 | $2,549,052.00 | |
| 3/12/2015 | Robert J Margolis | Chairman | Sell | 107,374 | $79.24 | $8,508,315.76 | |
| 2/27/2015 | Robert J Margolis | Chairman | Sell | 21,000 | $74.29 | $1,560,090.00 | |
| 2/19/2015 | Robert J Margolis | Chairman | Sell | 21,000 | $73.12 | $1,535,520.00 | |
| 1/30/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $75.48 | $2,370,072.00 | |
| 1/23/2015 | Michael David Staffieri | COO | Sell | 21,869 | $76.05 | $1,663,137.45 | |
| 1/16/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $74.92 | $2,352,488.00 | |
| 1/8/2015 | Kim M Rivera | Insider | Sell | 1,111 | $75.10 | $83,436.10 | |
| 12/30/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $76.09 | $2,389,226.00 | |
| 12/29/2014 | Robert J Margolis | Chairman | Sell | 15,700 | $76.09 | $1,194,613.00 | |
| 12/19/2014 | Laura Mildenberger | Insider | Sell | 1,446 | $75.50 | $109,173.00 | |
| 12/18/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $74.67 | $2,344,638.00 | |
| 12/3/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $75.80 | $2,380,120.00 | |
| 12/1/2014 | Kim M Rivera | Insider | Sell | 6,503 | $76.08 | $494,748.24 | |
| 11/21/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $75.08 | $2,357,512.00 | |
| 11/11/2014 | Kent J Thiry | CEO | Sell | 344,938 | $74.52 | $25,704,779.76 | |
| 11/11/2014 | Robert J Margolis | Chairman | Sell | 250,000 | $75.09 | $18,772,500.00 | |
| 11/10/2014 | Berkshire Hathaway Inc | Major Shareholder | Buy | 944,418 | $74.11 | $69,990,817.98 | |
| 11/7/2014 | R. Ted Weschler | Major Shareholder | Buy | 820,018 | $74.10 | $60,763,333.80 | |
| 11/3/2014 | Roger Valine | Director | Sell | 7,185 | $77.85 | $559,352.25 | |
| 9/16/2014 | John M Nehra | Director | Sell | 20,000 | $73.91 | $1,478,200.00 | |
| 9/8/2014 | Kim M Rivera | Insider | Sell | 1,111 | $74.25 | $82,491.75 | |
| 8/27/2014 | Leanne M Zumwalt | VP | Sell | 3,214 | $74.57 | $239,667.98 | |
| 8/11/2014 | Jeanine Marie Jiganti | Insider | Sell | 2,500 | $72.14 | $180,350.00 | |
| 6/11/2014 | Kim M Rivera | Insider | Sell | 5,929 | $71.05 | $421,255.45 | |
| 5/29/2014 | Laura Mildenberger | Insider | Sell | 5,080 | $69.99 | $355,549.20 | |
| 5/16/2014 | Dennis Kogod | COO | Sell | 18,750 | $67.30 | $1,261,875.00 | |
| 5/16/2014 | Kent Thiry | CEO | Sell | 17,600 | $67.41 | $1,186,416.00 | |
| 5/15/2014 | James Hilger | CAO | Sell | 1,666 | $67.23 | $112,005.18 | |
| 5/15/2014 | Javier Rodriguez | CEO | Sell | 7,000 | $67.50 | $472,500.00 | |
| 5/12/2014 | Dennis Kogod | COO | Sell | 32,188 | $68.06 | $2,190,715.28 | |
| 5/8/2014 | Dennis Kogod | COO | Sell | 32,213 | $67.36 | $2,169,867.68 | |
| 5/7/2014 | Michael David Staffieri | COO | Sell | 2,633 | $67.30 | $177,200.90 | |
| 4/2/2014 | Michael David Staffieri | COO | Sell | 2,867 | $69.15 | $198,253.05 | |
| 3/20/2014 | Laura Mildenberger | Insider | Sell | 3,274 | $70.04 | $229,310.96 | |
| 2/26/2014 | R. Ted Weschler | major shareholder | Buy | 1,159,858 | $66.97 | $77,675,690.26 | |
| 2/21/2014 | John Nehra | Director | Sell | 40,000 | $65.81 | $2,632,400.00 | |
| 2/18/2014 | William Roper | Director | Sell | 42,519 | $66.37 | $2,821,986.03 | |
| 12/20/2013 | Laura Mildenberger | Insider | Sell | 10,417 | $62.53 | $651,375.01 | |
| 12/17/2013 | Allen Nissenson | Insider | Sell | 2,929 | $59.83 | $175,242.07 | |
| 12/9/2013 | Berkshire Hathaway Inc | major shareholder | Buy | 1,314,170 | $57.84 | $76,011,592.80 | |
| 11/8/2013 | R. Ted Weschler | major shareholder | Buy | 3,700,294 | $55.14 | $204,034,211.16 | |
| 7/5/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 110,309 | $114.01 | $12,576,329.09 | |
| 7/3/2013 | R. Ted Weschler | Major Shareholder | Buy | 639,200 | $114.78 | $73,367,376.00 | |
| 5/15/2013 | David T Shapiro | Insider | Sell | 8,779 | $129.80 | $1,139,514.20 | |
| 5/15/2013 | Dennis Kogod | COO | Sell | 21,130 | $129.47 | $2,735,701.10 | |
| 5/15/2013 | James K Hilger | CFO | Sell | 1,049 | $130.18 | $136,558.82 | |
| 5/15/2013 | Leanne M Zumwalt | VP | Sell | 13,209 | $129.59 | $1,711,754.31 | |
| 5/13/2013 | Kent J Thiry | CEO | Sell | 243,307 | $129.95 | $31,617,744.65 | |
| 5/13/2013 | Kim M Rivera | Insider | Sell | 1,672 | $129.70 | $216,858.40 | |
| 3/4/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 164,947 | $119.59 | $19,726,011.73 | |
| 3/4/2013 | Roger Valine | Director | Sell | 1,390 | $120.00 | $166,800.00 | |
| 2/27/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 211,889 | $116.56 | $24,697,781.84 | |
| 2/22/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 224,091 | $115.88 | $25,967,665.08 | |
| 2/19/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 323,070 | $116.73 | $37,711,961.10 | |
| 2/5/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 32,376 | $115.17 | $3,728,743.92 | |
| 2/4/2013 | Roger Valine | Director | Sell | 1,389 | $116.13 | $161,304.57 | |
| 1/16/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 42,400 | $111.33 | $4,720,392.00 | |
| 1/15/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 179,300 | $109.67 | $19,663,831.00 | |
| 1/10/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 187,898 | $109.54 | $20,582,346.92 | |
| 12/24/2012 | Dennis Kogod | COO | Sell | 12,736 | $111.00 | $1,413,696.00 | |
| 12/21/2012 | James K Hilger | CFO | Sell | 2,073 | $112.20 | $232,590.60 | |
| 12/6/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 635,633 | $106.20 | $67,504,224.60 | |
| 11/29/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 679,249 | $108.20 | $73,494,741.80 | |
| 11/26/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 412,050 | $110.38 | $45,482,079.00 | |
| 11/16/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 132,958 | $112.45 | $14,951,127.10 | |
| 11/12/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 548,823 | $112.15 | $61,550,499.45 | |
| 11/7/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 139,491 | $112.03 | $15,627,176.73 | |
| 11/2/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 254,750 | $112.20 | $28,582,950.00 | |
| 10/26/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 257,941 | $111.14 | $28,667,562.74 | |
| 10/17/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 63,928 | $109.56 | $7,003,951.68 | |
| 10/12/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 217,597 | $109.76 | $23,883,446.72 | |
| 10/9/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 67,946 | $107.71 | $7,318,463.66 | |
| 9/28/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 282,403 | $102.03 | $28,813,578.09 | |
| 8/8/2012 | Kent J Thiry | Chairman | Sell | 320,877 | $96.88 | $31,086,563.76 | |
| 8/7/2012 | William L Roper | Director | Sell | 23,019 | $95.95 | $2,208,673.05 | |
(Data available from 1/1/2013 forward)
Headline Trends for DaVita HealthCare Partners (NYSE:DVA)
Latest Headlines for DaVita HealthCare Partners (NYSE:DVA)
| Source: |
|
| Date | Headline |
|---|
 | DaVita HealthCare Partners (DVA) & Community Health Systems (CYH) Head-To-Head Survey
www.americanbankingnews.com - August 20 at 2:28 PM |
 | Earnings Review and Free Research Report: DaVita’s Diluted EPS Rocketed 150%
finance.yahoo.com - August 16 at 6:29 PM |
 | NxStage Medical Partners Dialyze Direct for On-Site Dialysis - Nasdaq
www.nasdaq.com - August 14 at 6:26 PM |
| Fresenius Medical banks on home dialysis with $2 bln NxStage acquisition
finance.yahoo.com - August 7 at 6:20 PM |
| DaVita HealthCare Partners Inc. (DVA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 5 at 5:06 PM |
| DaVita HealthCare Partners Inc. (NYSE:DVA) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - August 5 at 2:56 PM |
| Equities Analysts Issue Forecasts for DaVita HealthCare Partners Inc.'s FY2017 Earnings (NYSE:DVA)
www.americanbankingnews.com - August 4 at 11:36 AM |
| Buy It Like Buffett -- or Better
finance.yahoo.com - August 3 at 4:33 PM |
| KeyCorp Comments on DaVita HealthCare Partners Inc.'s FY2018 Earnings (DVA)
www.americanbankingnews.com - August 3 at 3:30 PM |
| DaVita HealthCare Partners Inc. (DVA) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 3 at 12:30 PM |
| William Blair Analysts Lower Earnings Estimates for DaVita HealthCare Partners Inc. (NYSE:DVA)
www.americanbankingnews.com - August 3 at 8:44 AM |
| SunTrust Banks Weighs in on DaVita HealthCare Partners Inc.'s Q3 2017 Earnings (DVA)
www.americanbankingnews.com - August 3 at 8:44 AM |
| DaVita (DVA) Beats Earnings and Revenue Estimates in Q2 - Nasdaq
www.nasdaq.com - August 2 at 6:58 PM |
| Edited Transcript of DVA earnings conference call or presentation 1-Aug-17 9:00pm GMT
finance.yahoo.com - August 2 at 6:58 PM |
| DaVita HealthCare Partners Inc. (NYSE:DVA) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - August 1 at 9:29 PM |
 | DaVita HealthCare Partners beats by $0.02, beats on revenue
seekingalpha.com - August 1 at 6:41 PM |
| Investor Network: DaVita Inc. to Host Earnings Call
finance.yahoo.com - August 1 at 6:41 PM |
| DaVita Inc. 2nd Quarter 2017 Results
finance.yahoo.com - August 1 at 6:41 PM |
| DaVita HealthCare beats Street 2Q forecasts
finance.yahoo.com - August 1 at 6:41 PM |
| DaVita, Inc. – Value Analysis (NYSE:DVA) : August 1, 2017
finance.yahoo.com - August 1 at 6:41 PM |
| DaVita earnings beat expectations, despite problems in California, overseas
finance.yahoo.com - August 1 at 6:41 PM |
| DaVita, Inc. breached its 50 day moving average in a Bullish Manner : DVA-US : July 31, 2017
finance.yahoo.com - July 31 at 5:52 PM |
| DaVita HealthCare Partners Inc. (DVA) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:26 AM |
| DaVita CEO Thiry ends speculation regarding 2018 gubernatorial bid
finance.yahoo.com - July 24 at 10:52 PM |
| What's in the Cards for DaVita (DVA) this Earnings Season? - Nasdaq
www.nasdaq.com - July 24 at 10:23 AM |
| What's in the Cards for DaVita (DVA) this Earnings Season?
finance.yahoo.com - July 24 at 10:23 AM |
| $3.83 Billion in Sales Expected for DaVita HealthCare Partners Inc. (DVA) This Quarter
www.americanbankingnews.com - July 19 at 12:21 PM |
| DaVita, Inc. breached its 50 day moving average in a Bullish Manner : DVA-US : July 18, 2017
finance.yahoo.com - July 18 at 7:37 PM |
| DaVita HealthCare Partners Inc. (NYSE:DVA) Expected to Post Earnings of $0.90 Per Share
www.americanbankingnews.com - July 17 at 8:12 PM |
 | Longtime physician practice name disappears in Tampa Bay
www.bizjournals.com - July 17 at 6:59 PM |
| Reviewing DaVita HealthCare Partners (NYSE:DVA) and Laboratory Corporation of America Holdings (LH)
www.americanbankingnews.com - July 17 at 12:18 AM |
| DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando
finance.yahoo.com - July 14 at 4:04 PM |
| DaVita HealthCare Partners Inc. (DVA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 11 at 5:34 PM |
| Davita Inc (DVA) Downgraded by BidaskClub
www.americanbankingnews.com - July 8 at 7:46 PM |
 | Robbins Arroyo LLP Investigates Whether DaVita Inc. (DVA) Misled Shareholders - Business Wire (press release)
www.businesswire.com - July 8 at 5:39 PM |
| Robbins Arroyo LLP Investigates Whether DaVita Inc. (DVA) Misled Shareholders
finance.yahoo.com - July 8 at 10:20 AM |
| DaVita Inc. Schedules 2nd Quarter 2017 Investor Conference Call
finance.yahoo.com - July 5 at 6:46 PM |
| DaVita HealthCare Partners Inc. (DVA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 4 at 1:40 PM |
 | DaVita Medical Group Recognized for Excellence in Coordinated Care - PR Newswire (press release)
www.prnewswire.com - June 29 at 7:35 PM |
| DaVita Medical Group Recognized for Excellence in Coordinated Care
finance.yahoo.com - June 29 at 7:35 PM |
| Brokers Set Expectations for DaVita HealthCare Partners Inc.'s FY2017 Earnings (DVA)
www.americanbankingnews.com - June 28 at 8:02 AM |
| Morning Movers: Arconic Tumbles, DaVita Drops, Coach Rises
finance.yahoo.com - June 26 at 5:44 PM |
| Patient-Steering Allegations Only One Reason DaVita Shares Getting Downgraded
finance.yahoo.com - June 26 at 5:44 PM |
| DaVita HealthCare Partners Inc. (DVA) Stock Rating Lowered by Jefferies Group LLC
www.americanbankingnews.com - June 26 at 12:52 PM |
 | Investigation Relating to 401(k) Plans of DaVita Inc. (NYSE:DVA) Commenced by Stull, Stull & Brody
feeds.benzinga.com - June 23 at 8:59 PM |
| DaVita HealthCare Partners Inc. (DVA) Expected to Announce Quarterly Sales of $3.83 Billion
www.americanbankingnews.com - June 23 at 3:18 PM |
| Zacks: Brokerages Expect DaVita HealthCare Partners Inc. (DVA) Will Post Earnings of $0.90 Per Share
www.americanbankingnews.com - June 21 at 6:10 PM |
| Is DaVita a Suitable Stock for Value Investors?
finance.yahoo.com - June 20 at 5:32 PM |
| ETFs with exposure to DaVita, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 6:44 PM |
| Dr. David Mahoney Named Chief Medical Officer of Lifeline Vascular Access
finance.yahoo.com - June 19 at 1:42 PM |
DaVita HealthCare Partners (DVA) Chart for Tuesday, August, 22, 2017
